The US FDA has approved Cobenfy, a new antipsychotic for schizophrenia that targets cholinergic receptors instead of dopamine receptors. Developed by Bristol Myers Squibb, it combines xanomeline and trospium chloride to treat schizophrenia symptoms. The drug met its primary endpoints in phase 3 trials, showing significant reductions in symptoms compared to placebo. It has a better side-effect profile than other antipsychotics and does not cause weight gain or extrapyramidal symptoms. Experts believe this new approach to schizophrenia treatment is a major advance, but caution that its effectiveness and tolerability need to be tested in real clinical settings. The company has launched the Cobenfy Cares program to support patients.
Source link
FDA OKs First-in-Class Antipsychotic for Schizophrenia
